The 14 most recent market catalysts affecting $BEAM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 10, 2026
Corporate Catalyst
Bullish
Impact 95
Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel
Beam Therapeutics has announced highly positive topline data from its pivotal BEACON Phase 1/2 trial for risto-cel, an investigational one-time autologous cell therapy for sickle c…
Nov 5, 2026
Corporate Catalyst
Neutral
Impact 55
JonesTrading Initiates Coverage on Beam Therapeutics with Buy Rating
JonesTrading has initiated coverage on Beam Therapeutics (BEAM) with a 'Buy' rating and a $35 price target. This event is significant as new analyst coverage, especially with a pos…
Nov 4, 2026
Corporate Catalyst
Neutral
Impact 65
Beam Therapeutics to Present Updated BEACON Trial Data at 68th ASH Annual Meeting
Beam Therapeutics is set to present updated data from its BEACON Phase 1/2 clinical trial for risto-cel, a sickle cell disease therapy, at the ASH Annual Meeting in December 2026. …
Nov 3, 2026
Corporate Catalyst
Bullish
Impact 55
Wedbush Adjusts Price Target on Beam Therapeutics
Wedbush adjusted its price target for Beam Therapeutics from $28 to $30, maintaining an Outperform rating, after the company's third-quarter 2026 financial results. This action ind…
Nov 3, 2026
Corporate Catalyst
Bullish
Impact 60
Beam Therapeutics Receives Milestone Payment from Eli Lilly and Company
Beam Therapeutics received a milestone payment from Eli Lilly, signaling successful progress in their collaborative research and development efforts. This is positive for Beam as i…
Oct 15, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio has reiterated a 'Buy' rating and maintained an $80 price target for Beam Therapeutics. This action signals continued confidence fro…
Oct 13, 2026
Corporate Catalyst
Bullish
Impact 85
Beam Therapeutics To Present Initial Data From Ongoing Phase 1/2 Clinical Trial Evaluating BEAM-301 For Treatment Of Glycogen Storage Disease Type Ia At 33rd Annual Congress Of ESGCT
Beam Therapeutics announced initial positive Phase 1/2 clinical trial data for BEAM-301, a base editing therapy for Glycogen Storage Disease Type Ia (GSDIa). The data indicate clin…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 85
Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment
Beam Therapeutics announced updated Phase 1/2 trial data for BEAM-302, an experimental base-editing therapy for alpha-1 antitrypsin deficiency (AATD). The data showed promising eff…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 85
Beam Therapeutics Announces Updated Clinical Data From Its Phase 1/2 Trial Evaluating BEAM-302 For Alpha-1 Antitrypsin Deficiency; BEAM-302 Continues To Demonstrate Potential As One-Time Treatment For Both Lung And Liver Manifestations Of AATD
Beam Therapeutics released updated, positive clinical data from its Phase 1/2 trial for BEAM-302, a gene-editing therapy for Alpha-1 Antitrypsin Deficiency (AATD). The data highlig…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 75
Beam Therapeutics shares are trading higher after HC Wainwright & Co. reiterated its Buy rating on the stock and maintained a $80 price target.
The reiteration of a 'Buy' rating and an $80 price target by HC Wainwright & Co. acts as a strong positive catalyst for Beam Therapeutics. This analyst endorsement signals confiden…
Aug 25, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio has reaffirmed his 'Buy' rating and $80 price target for Beam Therapeutics. This action signals that the analyst's outlook on the co…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 95
Beam Therapeutics Q2 EPS $(1.18) Misses $(1.11) Estimate, Sales $490.000K Miss $16.370M Estimate
Beam Therapeutics announced Q2 results that fell significantly short of analyst estimates. The company reported a loss of $(1.18) per share against an estimate of $(1.11), and sale…
Jul 23, 2026
Corporate Catalyst
Neutral
Impact 55
Beam Therapeutics To Present Updated Clinical Data From Phase 1/2 Trial Evaluating BEAM-302 For Alpha-1 Antitrypsin Deficiency At ERS Congress 2026
Beam Therapeutics has announced a future event: the presentation of updated clinical data for its BEAM-302 program at the ERS Congress in September 2026. This is a forward-looking …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.